These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 29909520

  • 1. Lapatinib in combination with paclitaxel plays synergistic antitumor effects on esophageal squamous cancer.
    Guo XF, Li SS, Zhu XF, Dou QH, Liu D.
    Cancer Chemother Pharmacol; 2018 Sep; 82(3):383-394. PubMed ID: 29909520
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
    Wainberg ZA, Anghel A, Desai AJ, Ayala R, Luo T, Safran B, Fejzo MS, Hecht JR, Slamon DJ, Finn RS.
    Clin Cancer Res; 2010 Mar 01; 16(5):1509-19. PubMed ID: 20179222
    [Abstract] [Full Text] [Related]

  • 8. Pingyangmycin downregulates the expression of EGFR and enhances the effects of cetuximab on esophageal cancer cells and the xenograft in athymic mice.
    Gong JH, Liu XJ, Li Y, Zhen YS.
    Cancer Chemother Pharmacol; 2012 May 01; 69(5):1323-32. PubMed ID: 22311160
    [Abstract] [Full Text] [Related]

  • 9. Dual Inhibition of EGFR and IGF-1R Signaling Leads to Enhanced Antitumor Efficacy against Esophageal Squamous Cancer.
    Kang J, Guo Z, Zhang H, Guo R, Zhu X, Guo X.
    Int J Mol Sci; 2022 Sep 08; 23(18):. PubMed ID: 36142299
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. MS-275 combined with cisplatin exerts synergistic antitumor effects in human esophageal squamous cell carcinoma cells.
    Liu T, Guan F, Wang Y, Zhang Z, Li Y, Cui Y, Li Z, Liu H, Zhang Y, Wang Y, Ma S.
    Toxicol Appl Pharmacol; 2020 May 15; 395():114971. PubMed ID: 32217144
    [Abstract] [Full Text] [Related]

  • 12. Ursolic Acid Accelerates Paclitaxel-Induced Cell Death in Esophageal Cancer Cells by Suppressing Akt/FOXM1 Signaling Cascade.
    Meng RY, Jin H, Nguyen TV, Chai OH, Park BH, Kim SM.
    Int J Mol Sci; 2021 Oct 25; 22(21):. PubMed ID: 34768915
    [Abstract] [Full Text] [Related]

  • 13. Tunicamycin potentiates paclitaxel-induced apoptosis through inhibition of PI3K/AKT and MAPK pathways in breast cancer.
    Huang S, Wang D, Zhang S, Huang X, Wang D, Ijaz M, Shi Y.
    Cancer Chemother Pharmacol; 2017 Oct 25; 80(4):685-696. PubMed ID: 28779263
    [Abstract] [Full Text] [Related]

  • 14. Lapatinib, a Dual Inhibitor of Epidermal Growth Factor Receptor (EGFR) and HER-2, Enhances Radiosensitivity in Mouse Bladder Tumor Line-2 (MBT-2) Cells In Vitro and In Vivo.
    Mu Y, Sun D.
    Med Sci Monit; 2018 Aug 20; 24():5811-5819. PubMed ID: 30125265
    [Abstract] [Full Text] [Related]

  • 15. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
    Huang W, Wu QD, Zhang M, Kong YL, Cao PR, Zheng W, Xu JH, Ye M.
    Cancer Lett; 2015 Jan 28; 356(2 Pt B):862-71. PubMed ID: 25449780
    [Abstract] [Full Text] [Related]

  • 16. The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38.
    LaBonte MJ, Manegold PC, Wilson PM, Fazzone W, Louie SG, Lenz HJ, Ladner RD.
    Int J Cancer; 2009 Dec 15; 125(12):2957-69. PubMed ID: 19536776
    [Abstract] [Full Text] [Related]

  • 17. (-)-Oleocanthal Combined with Lapatinib Treatment Synergized against HER-2 Positive Breast Cancer In Vitro and In Vivo.
    Siddique AB, Ebrahim HY, Akl MR, Ayoub NM, Goda AA, Mohyeldin MM, Nagumalli SK, Hananeh WM, Liu YY, Meyer SA, El Sayed KA.
    Nutrients; 2019 Feb 15; 11(2):. PubMed ID: 30781364
    [Abstract] [Full Text] [Related]

  • 18. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer.
    Younes MN, Yazici YD, Kim S, Jasser SA, El-Naggar AK, Myers JN.
    Clin Cancer Res; 2006 Jun 01; 12(11 Pt 1):3425-34. PubMed ID: 16740767
    [Abstract] [Full Text] [Related]

  • 19. Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells.
    O'Donovan N, Byrne AT, O'Connor AE, McGee S, Gallagher WM, Crown J.
    Invest New Drugs; 2011 Oct 01; 29(5):752-9. PubMed ID: 20229355
    [Abstract] [Full Text] [Related]

  • 20. A multi-kinase inhibitor APG-2449 enhances the antitumor effect of ibrutinib in esophageal squamous cell carcinoma via EGFR/FAK pathway inhibition.
    Luo QY, Zhou SN, Pan WT, Sun J, Yang LQ, Zhang L, Qiu MZ, Yang DJ.
    Biochem Pharmacol; 2021 Jan 01; 183():114318. PubMed ID: 33159967
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.